Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

MAIN-CAV: Phase III Randomized Trial of Maintenance Cabozantinib and Avelumab vs Maintenance Avelumab After First-Line Platinum-Based Chemotherapy in Patients With Metastatic Urothelial Cancer

NCT05092958 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT05092958
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05092958 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
MAIN-CAV: Phase III Randomized Trial of Maintenance Cabozantinib and Avelumab vs Maintenance Avelumab After First-Line Platinum-Based Chemotherapy in Patients With Metastatic Urothelial Cancer
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 3
Overall status
Active, not recruiting
Start date
June 3, 2022
Completion date
July 15, 2029
Enrollment
654 (estimated)
Sites
275

Conditions

As the registry lists them; a condition with its own page is linked.

advanced bladder urothelial carcinoma, advanced renal pelvis urothelial carcinoma, advanced ureter urothelial carcinoma, advanced urethral urothelial carcinoma, metastatic bladder urothelial carcinoma, metastatic renal pelvis urothelial carcinoma, metastatic ureter urothelial carcinoma, metastatic urethral urothelial carcinoma, stage iii bladder cancer ajcc v8, stage iii renal pelvis and ureter cancer ajcc v8, stage iii renal pelvis cancer ajcc v8, stage iii ureter cancer ajcc v8, stage iii urethral cancer ajcc v8, stage iv bladder cancer ajcc v8, stage iv renal pelvis and ureter cancer ajcc v8, stage iv renal pelvis cancer ajcc v8, stage iv ureter cancer ajcc v8, stage iv urethral cancer ajcc v8